SRPT RNA FDA - random bizarre thought suitable to a Halloween night episode of Twilight Zone (i.e. Not real world but interesting)::
I've noted previously in some PMs that arguably the strongest case for SRPT efficacy is the RNA data - since they should share close to the same MOA. One interesting concept (albeit virtually impossible to envision happening in the real world) would be a collaborative deal between SRPT and RNA. Full data sharing, and using the same biomarker techniques to provide evidence that they do, in fact, produce similar results.
SRPT gains access to a variety of general data and efficacy data we know they need (e.g. Historical controls and much better data to judge who is most likely to benefit), ... .
RNA gets a significant percentage of SRPTs revenues for this version of etep (vs the risk that SRPT, if ever approved and with efficacy remotely similar to prosensa, will take all the market due to Prosensa adverse events).
Ok, now back to your regularly scheduled programming.
